Reining in prescription drug prices
Past Event
Paper: Framework for negotiation in Part D of Medicare
Paper: Framework for negotiation in Part D of Medicare
Paper: Can importation address high generic drug prices?
Paper: Removing barriers to competition in pharmaceutical markets
Panel: The politics of prescription drugs
Spending on prescription drugs in the U.S. has been increasing rapidly over the past few years, fueled by the introduction of expensive new drugs and price hikes on existing drugs. While the public demands new and better cures, polls suggest that they also overwhelmingly want the government to rein in prices. With prescription drug spending now accounting for roughly $1 of every $6 spent on health care, controlling pharmaceutical spending is also important to controlling health spending more broadly. How can we slow the pace of prescription drug increases without discouraging innovation and discovery?
On May 2, the Hutchins Center on Fiscal and Monetary Policy and the Center for Health Policy at Brookings hosted a forum on policies to lower prescription drug prices. The event began with presentations of three proposals aimed at reducing prescription drug prices, followed by a panel discussion on the proposals from a variety of perspectives. The event closed with a panel on the politics of prescription drug reform.
Read the policy brief: Ten challenges in the prescription drug market—and ten solutions
Related Content
Agenda
Opening remarks
Louise Sheiner
The Robert S. Kerr Senior Fellow - Economic Studies
Policy Director - The Hutchins Center on Fiscal and Monetary Policy
Session Materials
Paper: Framework for negotiation in Part D of Medicare
Paul B. Ginsburg
Director - USC-Brookings Schaeffer Initiative for Health Policy
Leonard D. Schaeffer Chair in Health Policy Studies
Senior Fellow - Economic Studies
Richard Frank
Margaret T. Morris Professor of Health Economics in the Department of Health Care Policy - Harvard Medical School
Richard J. Zeckhauser
Frank P. Ramsey Professor of Political Economy - Harvard Kennedy School of Government
Session Materials
Paper: Can importation address high generic drug prices?
Paul B. Ginsburg
Director - USC-Brookings Schaeffer Initiative for Health Policy
Leonard D. Schaeffer Chair in Health Policy Studies
Senior Fellow - Economic Studies
Thomas Bollyky
Senior Fellow for Global Health, Economics, and Development - Council on Foreign Relations (CFR)
Aaron Kesselheim
Associate Professor of Medicine - Brigham and Women’s Hospital and Harvard Medical School
Session Materials
Paper: Removing barriers to competition in pharmaceutical markets
Paul B. Ginsburg
Director - USC-Brookings Schaeffer Initiative for Health Policy
Leonard D. Schaeffer Chair in Health Policy Studies
Senior Fellow - Economic Studies
Fiona Scott Morton
Theodore Nierenberg Professor of Economics - Yale School of Management
Lysle Boller
Statistician - Yale School of Management
Session Materials
Panel: Perspectives from the field
Louise Sheiner
The Robert S. Kerr Senior Fellow - Economic Studies
Policy Director - The Hutchins Center on Fiscal and Monetary Policy
Troyen Brennan
Executive Vice President and Chief Medical Officer - CVS Health
Jennifer Bryant
Senior Vice President, Policy and Research - Pharmaceutical Research and Manufacturers of America (PhRMA)
Steven Pearson
President - Institute for Clinical and Economic Review (ICER)
Rachel Sachs
Associate Professor of Law - Washington University School of Law
Panel: The politics of prescription drugs
David Wessel
Director - The Hutchins Center on Fiscal and Monetary Policy
Senior Fellow - Economic Studies
Henry Waxman
Chairman - Waxman Strategies
More Information
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.
